STERIS (NYSE:STE) Posts Earnings Results, Misses Expectations By $0.03 EPS

Posted by Brenda Bartman on May 11th, 2026

STERIS (NYSE:STE – Get Free Report) posted its quarterly earnings data on Monday. The medical equipment provider reported $2.83 EPS for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03), FiscalAI reports. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. STERIS had a net margin of 12.15% and a return on equity of 14.34%. STERIS updated its FY 2027 guidance to 11.100-11.300 EPS.

STERIS Stock Performance

Shares of NYSE STE traded down $5.50 during trading on Monday, reaching $201.95. The stock had a trading volume of 1,011,024 shares, compared to its average volume of 773,466. STERIS has a one year low of $195.14 and a one year high of $269.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. The stock has a market cap of $19.81 billion, a PE ratio of 28.17 and a beta of 0.95. The firm’s 50 day moving average price is $224.30 and its two-hundred day moving average price is $244.27.

STERIS Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s payout ratio is 35.15%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on STE. Weiss Ratings cut STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, April 16th. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.20.

View Our Latest Stock Report on STE

Insider Activity at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the transaction, the director directly owned 705 shares of the company’s stock, valued at approximately $167,233.05. This represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.07% of the company’s stock.

Institutional Trading of STERIS

Several hedge funds have recently added to or reduced their stakes in the business. Peapack Gladstone Financial Corp bought a new stake in STERIS in the second quarter worth approximately $200,000. Aptus Capital Advisors LLC acquired a new stake in shares of STERIS in the fourth quarter worth $200,000. Smartleaf Asset Management LLC lifted its stake in shares of STERIS by 20.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 646 shares of the medical equipment provider’s stock worth $165,000 after buying an additional 109 shares during the last quarter. Transamerica Financial Advisors LLC lifted its stake in shares of STERIS by 4,500.0% in the fourth quarter. Transamerica Financial Advisors LLC now owns 644 shares of the medical equipment provider’s stock worth $163,000 after buying an additional 630 shares during the last quarter. Finally, Quarry LP lifted its position in shares of STERIS by 65.2% during the 4th quarter. Quarry LP now owns 598 shares of the medical equipment provider’s stock worth $152,000 after purchasing an additional 236 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

About STERIS

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.